Literature DB >> 3224373

Collagen biosynthesis by a breast carcinoma cell strain and biopsy fragments of the primary tumour.

S Minafra1, C Luparello, F Rallo, I Pucci-Minafra.   

Abstract

Collagen biosynthesis was assayed in tissue fragments and in cultured neoplastic cells derived from primary ductal infiltrating carcinoma of the human breast. Neoplastic cells "in vitro" produce 3-4% of collagen with respect to the high molecular weight protein fraction. The neosynthesized collagen is mainly composed of alpha 1 (I) chains, which may be assembled as homotrimer molecules, as indicated by their resistance to pepsin digestion. In tissue fragments, (where neoplastic and host stromal cells coexist), the collagen percentage increases up to 15-20% and more than one polypeptide chain is produced. Present data suggest that neoplastic cells "in vivo" contribute to the deposition of collagen components, actively synthesizing a certain amount of the type I-trimer, which is a significant component of the "scirrhous" stroma (Minafra et al.1984; Pucci Minafra et al, 1985). This phenomenon is interpreted as one of the numerous interrelationships occurring at the cell-matrix interface during the malignant growth.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3224373     DOI: 10.1016/0309-1651(88)90053-7

Source DB:  PubMed          Journal:  Cell Biol Int Rep        ISSN: 0309-1651


  9 in total

1.  Molecular mechanism of force induced stabilization of collagen against enzymatic breakdown.

Authors:  Shu-Wei Chang; Brendan P Flynn; Jeffrey W Ruberti; Markus J Buehler
Journal:  Biomaterials       Date:  2012-03-06       Impact factor: 12.479

2.  Carcinomas contain a matrix metalloproteinase-resistant isoform of type I collagen exerting selective support to invasion.

Authors:  Elena Makareeva; Sejin Han; Juan Carlos Vera; Dan L Sackett; Kenn Holmbeck; Charlotte L Phillips; Robert Visse; Hideaki Nagase; Sergey Leikin
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

3.  Structural and mechanical differences between collagen homo- and heterotrimers: relevance for the molecular origin of brittle bone disease.

Authors:  Shu-Wei Chang; Sandra J Shefelbine; Markus J Buehler
Journal:  Biophys J       Date:  2012-02-07       Impact factor: 4.033

4.  Molecular mechanism of type I collagen homotrimer resistance to mammalian collagenases.

Authors:  Sejin Han; Elena Makareeva; Natalia V Kuznetsova; Angela M DeRidder; Mary Beth Sutter; Wolfgang Losert; Charlotte L Phillips; Robert Visse; Hideaki Nagase; Sergey Leikin
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

5.  Segregation of type I collagen homo- and heterotrimers in fibrils.

Authors:  Sejin Han; Daniel J McBride; Wolfgang Losert; Sergey Leikin
Journal:  J Mol Biol       Date:  2008-08-09       Impact factor: 5.469

Review 6.  Collagen induced MMP-2 activation in human breast cancer.

Authors:  E W Thompson; M Yu; J Bueno; L Jin; S N Maiti; F L Palao-Marco; H Pulyaeva; J W Tamborlane; R Tirgari; I Wapnir
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

7.  3D collagen architecture regulates cell adhesion through degradability, thereby controlling metabolic and oxidative stress.

Authors:  Daniel O Velez; Sural K Ranamukhaarachchi; Aditya Kumar; Rishi N Modi; Esther W Lim; Adam J Engler; Christian M Metallo; Stephanie I Fraley
Journal:  Integr Biol (Camb)       Date:  2019-05-01       Impact factor: 2.192

8.  A new cell line (8701-BC) from primary ductal infiltrating carcinoma of human breast.

Authors:  S Minafra; V Morello; F Glorioso; A M La Fiura; R M Tomasino; S Feo; D McIntosh; D E Woolley
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

9.  Structural basis of homo- and heterotrimerization of collagen I.

Authors:  Urvashi Sharma; Loïc Carrique; Sandrine Vadon-Le Goff; Natacha Mariano; Rainier-Numa Georges; Frederic Delolme; Peppi Koivunen; Johanna Myllyharju; Catherine Moali; Nushin Aghajari; David J S Hulmes
Journal:  Nat Commun       Date:  2017-03-10       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.